PL437038A1 - Pochodna dikarboksyimidu do zastosowania w leczeniu nowotworów - Google Patents

Pochodna dikarboksyimidu do zastosowania w leczeniu nowotworów

Info

Publication number
PL437038A1
PL437038A1 PL437038A PL43703821A PL437038A1 PL 437038 A1 PL437038 A1 PL 437038A1 PL 437038 A PL437038 A PL 437038A PL 43703821 A PL43703821 A PL 43703821A PL 437038 A1 PL437038 A1 PL 437038A1
Authority
PL
Poland
Prior art keywords
treatment
cancer
neoplasm
dicarboximide derivative
dicarboximide
Prior art date
Application number
PL437038A
Other languages
English (en)
Inventor
Urszula Wojda
Marek GRYZIK
Grażyna HOSER
Mykola ZDIORUK
Iga STUKAN
Marcin Cieślak
Karolina Królewska-Golińska
Barbara Nawrot
Mariola Napiórkowska
Original Assignee
Instytut Biologii Doświadczalnej Im. M. Nenckiego Polskiej Akademii Nauk
Centrum Badań Molekularnych i Makromolekularnych Polskiej Akademii Nauk
Warszawski Uniwersytet Medyczny
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Instytut Biologii Doświadczalnej Im. M. Nenckiego Polskiej Akademii Nauk, Centrum Badań Molekularnych i Makromolekularnych Polskiej Akademii Nauk, Warszawski Uniwersytet Medyczny filed Critical Instytut Biologii Doświadczalnej Im. M. Nenckiego Polskiej Akademii Nauk
Priority to PL437038A priority Critical patent/PL437038A1/pl
Priority to PCT/IB2022/051411 priority patent/WO2022175858A1/en
Publication of PL437038A1 publication Critical patent/PL437038A1/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/4035—Isoindoles, e.g. phthalimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56—Ring systems containing three or more rings
    • C07D209/58—[b]- or [c]-condensed
    • C07D209/72—4,7-Endo-alkylene-iso-indoles
    • C07D209/76—4,7-Endo-alkylene-iso-indoles with oxygen atoms in positions 1 and 3

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Przedmiotem wynalazku jest związek BK 124.1, o wzorze I: do zastosowania w leczeniu nowotworów, przy czym nowotworem jest białaczka lub inny nowotwór charakteryzujący się klonalnym wzrostem liczby białych krwinek, przy czym nowotwór wykazuje oporność na dotychczasowe leczenie, w szczególności oporność wielolekową.
PL437038A 2021-02-17 2021-02-17 Pochodna dikarboksyimidu do zastosowania w leczeniu nowotworów PL437038A1 (pl)

Priority Applications (2)

Application Number Priority Date Filing Date Title
PL437038A PL437038A1 (pl) 2021-02-17 2021-02-17 Pochodna dikarboksyimidu do zastosowania w leczeniu nowotworów
PCT/IB2022/051411 WO2022175858A1 (en) 2021-02-17 2022-02-17 Dicarboximide derivative for use in cancer treatment

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PL437038A PL437038A1 (pl) 2021-02-17 2021-02-17 Pochodna dikarboksyimidu do zastosowania w leczeniu nowotworów

Publications (1)

Publication Number Publication Date
PL437038A1 true PL437038A1 (pl) 2022-08-22

Family

ID=81326911

Family Applications (1)

Application Number Title Priority Date Filing Date
PL437038A PL437038A1 (pl) 2021-02-17 2021-02-17 Pochodna dikarboksyimidu do zastosowania w leczeniu nowotworów

Country Status (2)

Country Link
PL (1) PL437038A1 (pl)
WO (1) WO2022175858A1 (pl)

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL228995B1 (pl) * 2012-07-16 2018-05-30 Centrum Badan Molekularnych I Makromolekularnych Polskiej Akademii Nauk Nowe, podstawione pochodne dikarboksyimidów, ewentualnie w postaci farmaceutycznie dopuszczalnej soli oraz ich zastosowanie
WO2015175846A2 (en) * 2014-05-16 2015-11-19 University Of Massachusetts Treating chronic myelogenous leukemia (cml)

Also Published As

Publication number Publication date
WO2022175858A1 (en) 2022-08-25

Similar Documents

Publication Publication Date Title
BR112021018950A2 (pt) Compostos de imidazolonilquinolina e seus usos terapêuticos
UY38076A (es) Derivados de tetrahidroquinazolina útiles como agentes anticáncer
ZA202005326B (en) Heteroaryl compounds as type ii irak inhibitors and uses hereof
CO2023016342A2 (es) Derivados de tetrahidroisoquinolina microbiocida
UY38070A (es) Derivados de quinazolina y piridopirimidina sustituidos útiles como agentes anticáncer
EA202092975A1 (ru) Селективные супрессоры рецептора эстрогена
EA202092248A1 (ru) Замещенные соединения 4-аминоизоиндолин-1,3-диона, их композиции и способы лечения ими
CR20230115A (es) Compuestos heterocíclicos
AR072016A1 (es) Derivados de isoxazol que funcionan como potenciadores de los receptores de glutamato
CL2025000822A1 (es) Inhibidores de pcsk9 y métodos de uso de los mismos.
MX2024013464A (es) Antagonistas del receptor de tipo toll 7/8 (tlr7/8) y usos de los mismos
MX2023009060A (es) Antagonistas de gpr84 y usos de estos.
EA201390877A1 (ru) Замещенные 6,6-конденсированные азотсодержащие гетероциклические соединения и их применение
CL2023002429A1 (es) Derivados novedosos de pirimidin-2-il sulfonamida
CL2023002903A1 (es) Derivados microbiocidas de quinolin/quinoxalin-benzotiazina.
CR20220116A (es) Compuestos heterocíclicos
MX2023009059A (es) Antagonistas de gpr84 y usos de estos.
AR118194A1 (es) Derivados heterociclos bicíclicos condensados como plaguicida
EA201992090A1 (ru) ДЕЙТЕРИРОВАННЫЕ СОЕДИНЕНИЯ ИМИДАЗО[4,5-c]ХИНОЛИН-2-ОНА И ИХ ПРИМЕНЕНИЕ В ЛЕЧЕНИИ РАКА
ZA202402459B (en) Compounds for regulating trained immunity, and their methods of use
MX358428B (es) Composiciones catalizadoras novedosas y metodos para su elaboracion y uso.
MX2024003130A (es) Amida 1,4-dihidro-1,6-naftiridina sustituida y uso de la misma.
CR20240173A (es) Compuestos de cd73
MX2023015408A (es) Inhibidores de transglutaminasas.
CL2024003171A1 (es) Gamma-hidroxibutirato que administra compuestos y procesos para su fabricación y uso